Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07325526 · ClinicalTrials.gov registry record · Phase 2

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

A Phase 2 study of Liver Cirrhosis, sponsored by Boehringer Ingelheim.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
20
Study locations

NCT07325526 is a Phase 2 study of Liver Cirrhosis that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 30 participants, below the 1,003-participant average among 15 other Liver Cirrhosis trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07325526, a Phase 2 study of Liver Cirrhosis, is actively recruiting participants, sponsored by Boehringer Ingelheim.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
20
Study locations

Study Summary

This study is open to adults with a type of confirmed liver condition called compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH). The purpose of this study is to find out how well a study medicine called BI 3802876 is tolerated in people with this condition. The study looks at how different doses of BI 3802876 are handled by the body. BI 3802876 is being developed to improve liver health in people living with this liver condition. Participants are put in 3 different dose groups randomly, which means by chance. Participants within a group get BI 3802876 or placebo. Placebo looks like BI 3802876 but does not contain any medicine. Participants have more than twice the chance of receiving BI 3802876 than placebo. The study medicine is given as an infusion into a vein. Participants are in the study for about half a year. During this time, they visit the study site 12 times. At 2 visits, participants get the study medicine. Doctors collect information on any health problems and take blood samples to check how BI 3802876 is handled by the body. They compare results between the groups.

Conditions Studied

Liver Cirrhosis

Interventions

  • DRUG Placebo
  • DRUG BI 3802876

Study Locations (20)

California

  • Southern California Research Center - Coronado
  • Orange County Research Center - Lake Forest
  • Pfleger Liver Institute - Los Angeles
  • Catalina Research Institute, LLC - Montclair
  • Velocity Clinical Research, San Diego - San Diego

Florida

  • University of Miami - Miami
  • Panax Clinical Research - Miami Lakes

Georgia

  • Piedmont Healthcare-Atlanta - Atlanta
  • Centricity Research Columbus Georgia Multispecialty - Columbus

Alabama

  • University of Alabama at Birmingham - Birmingham

Colorado

  • Peak Gastroenterology Associates - Colorado Springs

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

Michigan

  • Henry Ford Health System - Detroit

Minnesota

  • Mayo Clinic, Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2026-02-27
Est. Completion 2027-03-29
Phase Phase 2

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07325526

The ClinicalTrials.gov registry entry for NCT07325526 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,003-participant average among 15 other Liver Cirrhosis trials with a reported enrollment target (97% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Liver Cirrhosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07325526 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT07325526 about?

NCT07325526 is a clinical study titled "A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)". This study is open to adults with a type of confirmed liver condition called compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH). The purpose of this study is to find out how well a study medicine called BI 3802876 is tolerated in people with this condition. The stud...

What is the current status of trial NCT07325526?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-02-27. Estimated completion is 2027-03-29.

What conditions does trial NCT07325526 study?

This clinical trial studies the following conditions: Liver Cirrhosis.

What interventions are being tested in trial NCT07325526?

The interventions under investigation include: Placebo (DRUG), BI 3802876 (DRUG).

Who is sponsoring clinical trial NCT07325526?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07325526 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Liver Cirrhosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Liver Cirrhosis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.